Immune checkpoint inhibitors may increase risk of atherosclerotic cardiovascular disease

1. In patients diagnosed with stage III or IV non-small cell lung cancer (NSCLC), immune checkpoint inhibitors were associated with a greater risk of atherosclerotic cardiovascular disease. Evidence Rating Level: 2 (Good) Tumor treatment has become significantly better, specifically with the start of immune checkpoint inhibitors (ICIs). ICIs can be used to target programmed cell […]

The post Immune checkpoint inhibitors may increase risk of atherosclerotic cardiovascular disease first appeared on 2 Minute Medicine.